GMC 252

Drug Profile

GMC 252

Alternative Names: GMC-252; GMC-252-L-lysine salt

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genmedica Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Antioxidants; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Dyslipidaemias

Most Recent Events

  • 12 Oct 2017 Genmedica Therapeutics terminates a phase I trial in Healthy volunteers in United Kingdom as the study met its objective by dosing of 13 patients instead of 15 patients (NCT02744820)
  • 15 Dec 2016 Biomarkers information updated
  • 15 Apr 2016 Genmedica Therapeutics plans a phase I trial for Type-2 diabetes mellitus in United Kingdom (PO) (NCT02744820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top